Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare
Commercial prices vary markedly across urology practices. Among newly diagnosed men with traditional Medicare, those managed by practices with higher commercial price indices had lower odds of overtreatment, suggesting improved prostate cancer care quality.
Authors
- Brent K. Hollenbeck (ORCID: https://orcid.org/0000-0003-4840-1260)
- Christopher Dall (ORCID: https://orcid.org/0000-0002-2207-0531)
- Andrew M. Ryan (ORCID: https://orcid.org/0000-0002-2566-7763)
- Kassem Faraj (ORCID: https://orcid.org/0000-0002-2130-0446)
- Addison Shay (ORCID: https://orcid.org/0000-0003-1651-317X)
- Avinash Maganty (ORCID: https://orcid.org/0000-0001-6436-6667)
- Vahakn B. Shahinian (ORCID: https://orcid.org/0000-0003-3280-7821)
- Mary Oerline (ORCID: https://orcid.org/0000-0002-0264-6951)
- Arnav Srivastava (ORCID: https://orcid.org/0000-0002-9772-1415)
- Xiu Liu (ORCID: https://orcid.org/0000-0001-7818-8312)
- Samuel R. Kaufman
Institutions
- Brown University (US)
- University of Michigan (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1002/cncr.35633
- Citations
- 1
- Primary Topic
- Healthcare Policy and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- American Cancer Society
- Agency for Healthcare Research and Quality
- National Cancer Institute